Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. (Q48179574)

9 February 2018

title

Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. (English)

1 reference

9 February 2018

2

Hagop Kantarjian

1 reference

9 February 2018

6

Gautam Borthakur

1 reference

9 February 2018

4

Farhad Ravandi

1 reference

9 February 2018

5

Elias Jabbour

1 reference

9 February 2018

9

Sherry Pierce

1 reference

PubMed ID

28838278

9 February 2018

Guillermo Garcia-Manero

3

object named as

Guillermo Garcia-Manero

1 reference

9 February 2018

10

Jorge Cortes

1 reference

9 February 2018

8

Naveen Pemmaraju

1 reference

9 February 2018

Tapan M Kadia

11

object named as

Tapan M Kadia

1 reference

9 February 2018

Naval Daver

7

object named as

Naval Daver

1 reference

9 February 2018

author name string

Prajwal Boddu

1

1 reference

9 February 2018

publication date

25 August 2017

1 reference

9 February 2018

number of pages

4

1 reference

based on heuristic

inferred from page(s)

published in

Leukemia & Lymphoma

1 reference

9 February 2018

page(s)

1-4

1 reference

9 February 2018

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1365857

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1365857

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1365857

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1365857

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1365857

5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1365857

Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1365857

Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1365857

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1365857

Drastic effect of cell density on the cytotoxicity of daunorubicin and cytosine arabinoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1365857

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1365857

10.1080/10428194.2017.1365857

21 January 2018

Identifiers

DOI

1 reference

9 February 2018

PubMed ID

28838278

1 reference

9 February 2018